ALNY: TTR Growth vs Valuation — March 2026

Executive Summary

Company Overview

Alnylam Pharmaceuticals ($ALNY) develops and commercializes novel RNA interference therapeutics. The company focuses on genetically defined diseases and has built a leading position in transthyretin mediated amyloidosis, or TTR, while advancing programs across rare and common indications.

Key Products & Competitive Position

• Core Business: Discovery, development and commercialization of RNAi medicines delivered systemically and to specific tissues using proprietary delivery platforms.
• Key Products: Marketed TTR franchise products and other late stage candidates targeting hereditary ATTR, cardiomyopathy indications, and additional pipeline programs that expand the RNAi platform.
• Competitive Moat: Proprietary RNAi chemistry and delivery know how, clinical data depth in TTR disease, payer relationships for rare disease drugs, and a commercial infrastructure tuned to specialty and hospital channels.

Recent Developments

On March 26, 2026 Alnylam published a slide deck outlining its strategy to transform ATTR amyloidosis care and expand the TTR franchise. Analysts continue to publish bullish notes and maintain price targets above the current price. The company is preparing for Q1 2026 results expected April 30, and management commentary points toward additional geographic rollouts and label expansion work for TTR indications.

Financial Snapshot

Revenue & Earnings Trends

Alnylam reported FY25 revenue of roughly $3.7B on a trailing basis, with Q4 FY25 revenue around $1.1B and net income near $170M in that quarter. Revenue growth has accelerated as TTR franchise sales ramped, and trailing net income turned positive, producing a modest profit margin near 8.5 percent. Earnings per share on a trailing basis were about $2.25, though the reported diluted EPS data show some variability across quarters as investments in pipeline and commercial expansion continue.

Balance Sheet Highlights

The balance sheet appears healthy for a biotechnology growth company, with a current ratio around 2.76 and reported cash on the balance sheet above $2.9B in recent disclosures. Total debt levels have existed historically due to financing arrangements, but leverage metrics remain manageable relative to cash and cash equivalents. Free cash flow turned positive on a trailing basis, indicating improving cash generation as commercial sales scale.

Valuation Analysis

Historical Comparison

On trailing metrics Alnylam trades at materially higher multiples than many peers, reflecting premium pricing for a durable TTR franchise and expected growth. The current P/E of 134 is elevated, but the forward P/E near 32.9 indicates analysts expect rapid earnings growth. Compared to a 5 year look back, multiples are above historical averages, implying the market is pricing strong execution and market share expansion.

Fair Value Estimate

A blended approach that weights forward earnings multiples and a conservative DCF yields a central fair value area near the $400 to $460 range, which is broadly consistent with the analyst average price target near $449. Equity sensitivity is high because future revenues depend on continued label expansions and international rollouts. If management executes and new indications are approved, upside could be meaningfully higher, but missed expectations would compress value sharply.

Competitive Landscape

Key Competitors

Competitive Advantages

• Moat 1: Proprietary RNAi chemistry and delivery know how that supports high barriers to entry for new competitors.
• Moat 2: Deep clinical database and real world evidence in TTR amyloidosis that facilitate payer coverage and physician adoption.
• Moat 3: Commercial experience in rare disease markets, with established distribution and specialty sales channels.

Earnings Track Record

Recent Earnings History

Guidance Trend

Management has been guiding toward continued top line growth driven by TTR franchise expansion and geographic rollouts. Analysts have updated forward estimates to reflect accelerating revenues and improving margins, which is reflected in a forward P/E notably below the trailing ratio. Investors will be watching whether the company narrows the gap between guidance and consensus at the upcoming Q1 results.

Analyst Sentiment

Price Targets

• Low: $310
• Mean: $449.32 (+41.6% upside)
• High: $566

Recent Analyst Actions

Chardan Capital on March 25, 2026 maintained a Buy rating with a price target of $425. Across the sell side, several firms have maintained or raised targets as revenue momentum has become clearer. The analyst base is broadly constructive, with the majority recommending Buy or Strong Buy, suggesting consensus expectations are tilted to the upside.

Recent News & Catalysts

Key Developments

• Slide Deck on TTR Strategy (3/26/2026): Alnylam published a detailed slideshow describing progress in transforming ATTR care and plans to expand the TTR franchise, which reinforces management's commercial and regulatory road map.
• Market Commentary Items (3/26-3/30/2026): Broader market write ups noted stocks trading below estimated intrinsic values, and Alnylam was featured in analyst coverage discussing upside potential relative to fundamentals.
• Peer Data Points: Industry headlines such as negative data from a high dose obesity program at Wave Life highlight ongoing clinical risk in the biotech sector, which can spill over to sentiment for peer stocks including RNA-based companies.

Upcoming Catalysts

Technical Outlook

Trend Analysis

Price action shows a recovery from the 52-week low near $205.87 set in April 2025, with a strong bounce into 2026. The stock remains below its 52-week high by nearly 36 percent, reflecting a pullback from peak sentiment. Volatility has moderated, as indicated by a low beta near 0.4, and trading is likely being driven more by fundamental news than by broad market swings.

Key Levels

• Resistance: $350, $425
• Support: $280, $205.87

Bull vs Bear Case

Risks to Consider

Bottom Line

Action Items for Investors

• Long-term investors: Monitor pipeline readouts and commercial uptake metrics, and consider valuation sensitivity to different growth scenarios rather than relying on headline targets.
• Short-term traders: Watch Q1 2026 results, guidance commentary, and slide deck details for short term volatility catalysts, and size positions with tighter risk limits.
• Risk management: Given elevated multiples, maintain position sizing discipline, and use stop limits or defined exposure levels to manage downside scenarios.

What to Watch This Week

• Preparation for Q1 2026 earnings expected on 2026-04-30, watch pre-earnings analyst notes and estimate revisions.
• Any payer updates or country rollouts referenced in management communications or the investor slide deck published 3/26/2026.
• Peer clinical news, as sector headlines can shift sentiment for RNA and oligonucleotide companies quickly.